In this review:
- Dimethyl fumarate in radiologically isolated syndrome (ARISE)
- Autologous haematopoietic stem cell transplantation in progressive MS
- Immunadsorption versus double-dose methyl prednisolone in steroid-refractory MS (INCIDENT-MS)
- Discontinuation of first-line disease-modifying therapy in MS
- Tolebrutinib in patients with highly active MS
- B-lymphocyte-guided retreatment with rituximab
- Cyclophosphamide in acute treatment of severe neuroinflammatory disorders
- Alternative diagnosis in first-line referral for suspected MS
- Treating active MS following induction therapy
- Predicting the risk of long-term relapse in MOGAD
Please login below to download this issue (PDF)